Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, family medicine, and general surgery. The Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products. This segment offers dermocosmetic products under the Ceradan and TDF brands through medical professionals; health supplement products under the Ocean Health brand directly to consumers via retail channels; and scalp care products under the CG 210 brand through medical professionals. The Medical Hypermart and Digital segment wholesales pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. The segment also operates an online B2B platform; and WellAway, an e-pharmacy. In addition, it offers PLINEST and NEWEST Polynucleotides-HPTTM products; OXITHION, a skin brightening solution; and Nabota, a highpurity botulinum toxin. Further, the company provides pharmaceutical products, nutraceuticals, and medical devices for hospitals, polyclinics, specialists, and general practitioners. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.
Show more
-
Hyphens Pharma International Limited Annual General Meeting Notice
April 11, 2025
Key Points: The Company’s AGM will be held on April 28, 2025, at 10:00 a.m. The meeting will discuss and vote on several key resolutions,…
-
Hyphens Pharma Q3 Results: Revenue Growth Slows, Maintains “Add” Rating
November 14, 2024
Comprehensive Analysis of Hyphens Pharma and Market Peers Comprehensive Analysis of Hyphens Pharma International and Market Peers Broker: CGS International Date: November 13, 2024 Hyphens…
-
Hyphens Pharma Reports Mixed Q3 Results: Revenue Up, Profit Down
November 13, 2024
Hyphens Pharma Reports Strong Growth with 22.1% Revenue Increase in 9M2024 Hyphens Pharma Reports Strong Growth with 22.1% Revenue Increase in 9M2024 Hyphens Pharma International…
-
Hyphens Pharma Sees Mixed Q3 Results Amid Strong Year-to-Date Growth
November 13, 2024
Hyphens Pharma International Posts Strong Revenue Growth and Profit Boost in 2024 Hyphens Pharma International Posts Strong Revenue Growth and Profit Boost in 2024 Hyphens…
-
Hyphens Pharma Defies Odds: 32.6% Profit Surge Despite Challenging Quarter
November 13, 2024
Hyphens Pharma Posts Strong Revenue Growth in 9M2024 Despite Rising Costs Hyphens Pharma Posts Strong Revenue Growth in 9M2024 Despite Rising Costs Hyphens Pharma International…
-
Hyphens Pharma Defies Economic Headwinds: 22% Revenue Surge Despite Q3 Profit Dip
November 13, 2024
Hyphens Pharma Reports Solid Q3 and 9M Performance Amid Higher Costs Hyphens Pharma Reports Solid Q3 and 9M Performance Amid Higher Costs Hyphens Pharma International…
-
Hyphens Pharma International – A Healthy Pipeline Driving Revenue Growth and Profitability
September 12, 2024
Company Highlights: Hyphens Pharma International (HYP) has shown a strong performance in the first half of 2024, achieving record revenue of S$99.6 million, a significant…
-
Hyphens Pharma International: Growth Supported by a Healthy Product Pipeline
September 11, 2024
Hyphens Pharma International: Growth Supported by a Healthy Product Pipeline Overview: Hyphens Pharma International Ltd. (HYP) is a leading specialty pharmaceutical and consumer healthcare company…
